CareDx, Inc.
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- CareDx, Inc. CareDx, Inc. (Nasdaq: CDNA) operates as a leading precision medicine company focused on the discovery, development, and commercialization of diagnostic solutions, testing services, products, and digital healthcare tools for transplant patients and caregivers along the pre- and post-transplant journey. The company offers core products and services including AlloSure Kidney, AlloSure Heart, AlloSure Lung, and AlloMap Heart gene expression profiling tests, which utilize donor-derived cell-free DNA (dd-cfDNA) for noninvasive surveillance to detect organ injury and rejection in kidney, heart, and lung transplant recipients; AlloSeq and QTYPE for superior HLA typing with hybrid capture technology; HeartCare, combining AlloMap Heart and AlloSure Heart; digital solutions such as the AlloCare mobile app for patient medication management, health tracking, and care coordination, and transplant administration software like Ottr acquired via TransChart in 2021; transplant lab products for matching; and pharma services to accelerate biopharma clinical development. Founded in 1998 and headquartered in Brisbane, California, with principal operations in South San Francisco, California; Omaha, Nebraska; Fremantle, Australia; and Stockholm, Sweden, CareDx primarily generates revenue from the United States while serving over 150 U.S. transplant centers and more than 30,000 patients. Recent developments include the launch of AlloSure Plus (formerly AlloView), an AI-driven diagnostic platform integrating dd-cfDNA with clinical methods for improved rejection prediction; new IVD products and IVDR certification for AlloSeq Tx and QTYPE announced at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting; the launch of HistoMap Kidney, a tissue-based gene expression assay to characterize rejection phenotypes, planned for early 2026; partnerships such as with Leidos to transform the Organ Procurement and Transplantation Network, TC BioPharm for AML therapy trials using AlloCell testing, and agreements with Illumina and Cibiltech; installation of the EPIC environment and customer pilots; and strong Q3 2025 financial results with 21% revenue growth, 30% increase in patient and digital solutions revenue, and improved profitability.
Company News
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CareDx (CDNA) Upgraded to Strong Buy: Here's What You Should Know
Polen 5Perspectives Ultra-Small Growth Q3 2026 Portfolio Review
Baron Discovery Fund Q3 2026 Portfolio Activity
CareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing Growth
CareDx Announces Third KOAR Analysis Published in Transplantation
Why CareDx Stock Soared Today
CareDx, Inc. (CDNA) Q3 2026 Earnings Call Transcript
What CareDx (CDNA) Said on Its Q3 Earnings Call
CareDx (CDNA) Surpasses Q3 Earnings and Revenue Estimates
CareDx Announces Third Quarter 2026 Financial Results
CareDx to Report Q3 Earnings: Transplant Testing Growth in Focus
CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026
CareDx Inc (CDNA) Shares Fall 4.0% -- GF Value Says Still Overvalued
CareDx to Report Third Quarter 2026 Financial Results on October 29, 2026
Critical Contrast: CollPlant Biotechnologies (NASDAQ:CLGN) & CareDx (NASDAQ:CDNA)
CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?
Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently
5 Top-Ranked High-Efficiency Stocks With Strong Profit Potential
CareDx (NASDAQ:CDNA) Hits New 1-Year High – Time to Buy?